Moreover, considering tumor heterogeneity and the small size of our population, looking for ESR1 mutations may not be sufficient, since other mutations, such as in the MAPK, PI3K/AKT/mTOR, and CDK4/6 pathways, have been demonstrated to be involved in the mechanisms of resistance [7,34]. The gene discussed is MTOR; the disease is neoplasm.